141 related articles for article (PubMed ID: 11436282)
41. Mesalazine-induced lupus.
Timsit MA; Anglicheau D; Lioté F; Marteau P; Dryll A
Rev Rhum Engl Ed; 1997 Oct; 64(10):586-8. PubMed ID: 9385697
[TBL] [Abstract][Full Text] [Related]
42. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery.
Doherty G; Moss AC
Am J Gastroenterol; 2012 Mar; 107(3):487; author reply 487-8. PubMed ID: 22388032
[No Abstract] [Full Text] [Related]
43. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
44. [Acute pancreatitis--adverse effect of 5-aminosalicylic acid (mesalazine) in various galenic dosage forms].
Schwörer H; Ramadori G
Dtsch Med Wochenschr; 2000 Nov; 125(44):1328-30. PubMed ID: 11109415
[TBL] [Abstract][Full Text] [Related]
45. [Improved treatment of Crohn's disease].
Nau JY
Rev Med Suisse; 2005 May; 1(18):1241. PubMed ID: 15977716
[No Abstract] [Full Text] [Related]
46. You're the flight surgeon. Crohn's disease.
Hartwich SA
Aviat Space Environ Med; 2004 Aug; 75(8):716-7. PubMed ID: 15328792
[No Abstract] [Full Text] [Related]
47. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
Steinhart AH; Forbes A; Mills EC; Rodgers-Gray BS; Travis SP
Aliment Pharmacol Ther; 2007 Jun; 25(12):1389-99. PubMed ID: 17539978
[TBL] [Abstract][Full Text] [Related]
48. [Severe chronic interstitial nephritis associated with Crohn's disease, but not with mesalazine?].
Baumer P; Brocard JF; Kohn W; Bedossa P; Charpentier B
Gastroenterol Clin Biol; 1999 Dec; 23(12):1400-2. PubMed ID: 10642629
[No Abstract] [Full Text] [Related]
49. Severe exudative ascites as an initial presentation of Crohn's disease.
Tekin F; Vatansever S; Ozütemiz O; Musoğlu A; Ilter T
Turk J Gastroenterol; 2005 Sep; 16(3):171-3. PubMed ID: 16245232
[TBL] [Abstract][Full Text] [Related]
50. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation.
Tamura S; Ishida N; Miyazu T; Onoue S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Sugimoto K
Sci Rep; 2020 Dec; 10(1):21353. PubMed ID: 33288852
[TBL] [Abstract][Full Text] [Related]
51. [Mesalazine is without clinical effect in patients with Crohn disease].
Munck LK
Ugeskr Laeger; 2005 Jan; 167(3):302-3. PubMed ID: 15704804
[No Abstract] [Full Text] [Related]
52. A comparison of budesonide and mesalamine for active Crohn's disease.
Lowry PW; Sandborn WJ
Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
[No Abstract] [Full Text] [Related]
53. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto.
Frieri G; Pimpo MT; Andreoli A; Annese V; Comberlato M; Corrao G; Palumbo G; Sturniolo GC; Tonelli F; Caprilli R
Aliment Pharmacol Ther; 1999 May; 13(5):577-82. PubMed ID: 10233180
[TBL] [Abstract][Full Text] [Related]
54. Metastatic Crohn's disease: remission induced by mesalamine and prednisone.
Gilson MR; Elston LC; Pruitt CA
J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):476-9. PubMed ID: 10459127
[TBL] [Abstract][Full Text] [Related]
55. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions.
Delgado J; Delgado B; Sztarkier I; Cagnano E; Sperber AD; Fich A
Isr Med Assoc J; 2003 Dec; 5(12):897-8. PubMed ID: 14689766
[No Abstract] [Full Text] [Related]
56. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
[TBL] [Abstract][Full Text] [Related]
57. Relapsing tubulointerstitial nephritis in an adolescent with inflammatory bowel disease without aminosalicylate exposure.
Shahrani Muhammad HS; Peters C; Casserly LF; Dorman AM; Watts M
Clin Nephrol; 2010 Mar; 73(3):250-2. PubMed ID: 20178728
[TBL] [Abstract][Full Text] [Related]
58. Aminosalicylates and Elderly-onset Colonic Crohn's Disease-More Than Meets the Eye?
Limdi JK
J Crohns Colitis; 2017 Aug; 11(8):1022. PubMed ID: 28333225
[No Abstract] [Full Text] [Related]
59. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
[TBL] [Abstract][Full Text] [Related]
60. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
Feagan BG
Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
